0000000000266040

AUTHOR

Jürgen Deckert

showing 6 related works from this author

Sonstige psychotrope Substanzen

2007

Koffein (1,3,7-Trimethylxanthin; C8H10N4O12, Molekulargewicht 194,19) gehort zur Gruppe der naturlich vorkommenden Purine wie die strukturahnlichen Theophyllin (1,3-Dimethylxanthin) und Theobromin (3,7-Dimethylxanthin) (Abb. 5.1.1).

03 medical and health sciences0302 clinical medicine030212 general & internal medicine030217 neurology & neurosurgery3. Good health
researchProduct

MicroRNA hsa-miR-4717-5p regulates RGS2 and may be a risk factor for anxiety-related traits

2015

Regulator of G-protein Signaling 2 (RGS2) is a key regulator of G-protein-coupled signaling pathways involved in fear and anxiety. Data from rodent models and genetic analysis of anxiety-related traits and disorders in humans suggest down-regulation of RGS2 expression to be a risk factor for anxiety. Here we investigated, whether genetic variation in microRNAs mediating posttranscriptional down-regulation of RGS2 may be a risk factor for anxiety as well. 75 microRNAs predicted to regulate RGS2 were identified by four bioinformatic algorithms and validated experimentally by luciferase reporter gene assays. Specificity was confirmed for six microRNAs (hsa-miR-1271-5p, hsa-miR-22-3p, hsa-miR-3…

AdultMaleCandidate geneSingle-nucleotide polymorphismMIR4717ComorbidityBiologyBioinformaticsPolymorphism Single NucleotideCellular and Molecular NeuroscienceGenes ReporterRisk FactorsmedicineHumansIKBKEGenetic Predisposition to DiseaseAllelepanic disorderLuciferases3' Untranslated RegionsAgoraphobiaAllelesGenetic Association StudiesGenetics (clinical)miRNAGeneticsPanic disorderassociationComputational BiologyReproducibility of Resultsmedicine.diseaseAnxiety DisordersMicroRNAsPsychiatry and Mental healthGene Expression RegulationCase-Control StudiesLinear ModelsAnxiety sensitivityAnxietyFemalemedicine.symptomgene regulationRGS ProteinsAgoraphobiaAmerican Journal of Medical Genetics Part B-neuropsychiatric Genetics
researchProduct

The Effect of Age, Sex, Smoking and Co-Medication on Serum Levels of Venlafaxine and O-Desmethylvenlafaxine under Naturalistic Conditions

2012

Venlafaxine (VEN) is a modern antidepressant which exerts both serotonin and norepinephrine reuptake inhibition. In this study we examined the influence of age, sex, smoking, and co-medication on serum levels of VEN and its metabolite O-desmethylvenlafaxine (ODVEN) in patients treated with VEN under naturalistic conditions.We retrospectively evaluated 478 TDM analyses of VEN requested in the Pychiatric University Hospitals of Mainz, Regensburg, and Würzburg. The determination of serum levels was performed by virtually identical chromatographic methods in the TDM laboratories of the participating hospitals.Serum levels varied widely on each dose level. Women had about 30% higher dose-correct…

AdultMalemedicine.medical_specialtyAdolescentVenlafaxine HydrochlorideVenlafaxinePharmacokineticsDesvenlafaxine SuccinateInternal medicinemedicineHumansPharmacology (medical)DosingAgedRetrospective StudiesAged 80 and overSex Characteristicsbusiness.industrySmokingAge FactorsVenlafaxine HydrochlorideRetrospective cohort studyGeneral MedicineMiddle AgedCyclohexanolsPsychiatry and Mental healthAnesthesiaVenAntidepressive Agents Second-GenerationAntidepressantDrug Therapy CombinationFemaleDrug Monitoringbusinessmedicine.drugSex characteristicsPharmacopsychiatry
researchProduct

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

2017

AbstractTherapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug…

medicine.medical_specialtyPsychopharmacologyGuidelines as Topic030226 pharmacology & pharmacy03 medical and health sciencesNeuropharmacology0302 clinical medicinePharmacotherapyHealth caremedicineHumansPharmacology (medical)PsychiatryIntensive care medicinePsychotropic Drugsmedicine.diagnostic_testbusiness.industryMental DisordersGeneral Medicinemedicine.disease3. Good healthAntiparkinson drugNeuropsychopharmacologySubstance abusePsychiatry and Mental healthTolerabilityTherapeutic drug monitoringDrug Monitoringbusiness030217 neurology & neurosurgeryPharmacogeneticsPharmacopsychiatry
researchProduct

Mismatch or allostatic load? Timing of life adversity differentially shapes gray matter volume and anxious temperament

2015

Traditionally, adversity was defined as the accumulation of environmental events (allostatic load). Recently however, a mismatch between the early and the later (adult) environment (mismatch) has been hypothesized to be critical for disease development, a hypothesis that has not yet been tested explicitly in humans. We explored the impact of timing of life adversity (childhood and past year) on anxiety and depression levels (N = 833) and brain morphology (N = 129). Both remote (childhood) and proximal (recent) adversities were differentially mirrored in morphometric changes in areas critically involved in emotional processing (i.e. amygdala/hippocampus, dorsal anterior cingulate cortex, res…

0301 basic medicineMalestressful life eventschildhood maltreatmentEmotionsAnxietySocial EnvironmentDevelopmental psychology0302 clinical medicineGray MatterVBMChildadversitymedia_commonDepressionAdult Survivors of Child AbuseAllostasisBrainGeneral MedicineOrgan SizeMagnetic Resonance ImagingAllostatic loadmedicine.anatomical_structureAllostasisAnxietyFemalemedicine.symptomPsychologymismatchallostatic loadAdultCognitive Neurosciencemedia_common.quotation_subjectExperimental and Cognitive PsychologyAffect (psychology)AmygdalaLife Change Events03 medical and health sciencesYoung AdultmedicineHumansddc:610TemperamentAnterior cingulate cortexBrain morphometryOriginal ArticlesImage Enhancement030104 developmental biologyTemperament030217 neurology & neurosurgerySocial Cognitive and Affective Neuroscience
researchProduct

GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathw…

2017

Contains fulltext : 177350.pdf (Publisher’s version ) (Closed access) The molecular genetics of panic disorder (PD) with and without agoraphobia (AG) are still largely unknown and progress is hampered by small sample sizes. We therefore performed a genome-wide association study with a dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia Cognition Questionnaire (ACQ) in a sample of 1370 healthy German volunteers of the CRC TRR58 MEGA study wave 1. A genome-wide significant association was found between ACQ and single non-coding nucleotide variants of the GLRB gene (rs78726293, P=3.3 x 10-8; rs191260602, P=3.9 x 10-8). We followed up on this finding in a larger dimensional AC…

0301 basic medicineMaleStartle responseReflex StartleQH301 BiologyGenome-wide association studyGene mutationAnxiety0302 clinical medicineCognitionReceptors GlycineGene FrequencyGermanyGWASHyperekplexiaGeneticsPanic disordermedicine.diagnostic_testStartleBrainFearGLRBAnxiety DisordersPsychiatry and Mental healthSchizophreniaUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Panic DisorderFemalemedicine.symptomPsychologyBDCRC0321 Neuroscience. Biological psychiatry. NeuropsychiatryClinical psychologyAdultGenotypeNDASQH426 Genetics03 medical and health sciencesCellular and Molecular NeuroscienceQH301Fear networkSpastic mousemedicineHumansGenetic Predisposition to DiseaseMolecular BiologyQH426AgoraphobiaAllelesNeurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]Panic disorderOther Research Radboud Institute for Health Sciences [Radboudumc 0]medicine.diseaseStartle reaction030104 developmental biologyMCPCase-Control StudiesMutationRC0321030217 neurology & neurosurgeryAgoraphobiaGenome-Wide Association StudyMolecular psychiatry
researchProduct